What one share of Climb Bio holds
We are a clinical-stage biotechnology company committed to developing potential best-in-class therapeutics that address significant unmet need for patients living with immune-mediated diseases. We have built our pipeline by strategically acquiring or in-licensing product candidates that we believe have clear biological rationale, well-defined development pathways, and the potential to address multiple indications.
Climb Bio’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$0.82 |
|---|---|
| Capex (buildings and equipment) | $0.01 |
| Free cash flow | −$0.76 |
| Cash and investments | $4.17 |
| Book value | $4.17 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | — | −$10.49 | — | — | — | −$7.31 |
| 2021 | — | −$4.24 | — | — | — | — |
| 2022 | — | −$1.72 | — | — | — | $4.84 |
| 2023 | — | −$1.30 | $0.00 | −$0.76 | — | $3.88 |
| 2024 | — | −$1.53 | $0.00 | −$0.32 | — | $3.15 |
| 2025 | — | −$0.88 | $0.00 | −$0.80 | — | $3.36 |
Common questions about Climb Bio
How much does one share of Climb Bio earn?
Over the last 12 months, Climb Bio lost $0.82 for each share.
Does Climb Bio pay a dividend?
Climb Bio didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Climb Bio’s book value per share?
Climb Bio’s book value is $4.17 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Climb Bio have?
Each share of Climb Bio has $4.17 of cash and investments, as of June 30, 2026.
What is Climb Bio’s free cash flow per share?
−$0.76 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Climb Bio bought back shares?
Climb Bio’s share count rose about 3000% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.